



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

January 20th, 2015 6:00 – 8:30 p.m.

- | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| 1. Executive Session | 6:00 - 6:45 |
| <ul style="list-style-type: none">▪ Orientation presentation -GHS▪ Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2)) | |
| 2. Introductions and Approval of DUR Board Minutes
(Public Comment Prior to Board Action) | 6:45 - 6:45 |
| 3. DVHA Pharmacy Administration Updates | 6:45 - 6:50 |
| <ul style="list-style-type: none">▪ Updates | |
| 4. Medical Director Update | 6:50 - 6:55 |
| <ul style="list-style-type: none">▪ Clinical Programs Update▪ Prescriber Comments | |
| 5. GHS Presentation on Clinical/Reading Materials | 6:55-7:00 |
| 6. Follow-up Items from Previous Meetings | 7:00-7:20 |
| <ul style="list-style-type: none">▪ Vivitrol step-through for Opiate Dependence▪ Zohydro ER new formulation | |
| 7. RetroDUR/DUR
None this meeting | 7:20 – 7:20 |
| 8. Clinical Update: Drug Reviews
(Public comment prior to Board action) | 7:20 – 7:45 |
| Abbreviated New Drug Reviews-None | |
| Full New Drug Reviews | |
| <ul style="list-style-type: none">▪ Entyvio (vedolizumab) 300mg single-dose vial▪ Jublia (efinaconazole) 10% topical solution▪ Sivextro (tedizolid) 200 mg tablet▪ Tanzeum (albiglutide) for injection▪ Harvoni (90 mg ledipasvir and 400 mg sofosbuvir) tablet▪ Viekira pak (ombitasvir, paritaprevir, and ritonavir tablet, dasabuvir tablet)▪ Zohydro ER (hydrocodone bitartrate) extended-release capsules | |
| 9. Therapeutic Drug Classes – Periodic Review | 7:45 – 7:55 |
| <ul style="list-style-type: none">▪ (Public comment prior to Board action)
Sublingual Immunotherapy | |

10. New Managed Therapeutic Drug Classes **7:55 – 7:55**
(Public comment prior to Board action)
▪ None

11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products **7:55 – 8:25**
(Public comment prior to Board action)
▪ Hepatitis C update and recommendations
○ Sovaldi
○ Harvoni
○ Viekira Pak

12. General Announcements **8:25– 8:30**
Selected FDA Safety Alerts

- FDA recommends not using lidocaine to treat teething pain and requires new Boxed Warning (6/26/2014) <http://www.fda.gov/drugs/drugsafety/ucm402240.htm>
- Methylphenidate HCl ER tablets (generic Concerta) made by Mallinckrodt and Kudco: FDA concerns about therapeutic equivalence with 2 generic versions of Concerta tablets (11/13/2014) <http://www.fda.gov/drugs/drugsafety/ucm422568.htm>
- FDA reviews long-term antiplatelet therapy as preliminary trial data shows benefits but a higher risk of non-cardiovascular death (11/16/2014) <http://www.fda.gov/Drugs/DrugSafety/ucm423079.htm>
- FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate) (11/25/2014) <http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm>
- FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products 12/3/2014) <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm425317.htm>
- FDA reporting mental health drug ziprasidone (Geodon) associated with rare but potentially fatal skin reaction (12/11/2014) <http://www.fda.gov/Drugs/DrugSafety/ucm426391.htm>
- FDA has reviewed possible risks of pain medicine use during pregnancy (1/9/2015) <http://www.fda.gov/Drugs/DrugSafety/ucm429117.htm>

13. Adjourn **8:30**